tiprankstipranks
CareDx downgraded to Equal Weight from Overweight at Stephens
The Fly

CareDx downgraded to Equal Weight from Overweight at Stephens

Stephens analyst Mason Carrico downgraded CareDx to Equal Weight from Overweight with a price target of $9, down from $19, following the recent release of a new CMS billing policy that "significantly restricts" the use and frequency of transplant testing. The firm sees an immediate negative impact to revenue by eliminating HeartCare reimbursement and limiting use of AlloSure Kidney, adding that policy restrictions introduce considerable uncertainty around key revenue drivers and likely significantly shrinks the kidney transplant total addressable market. The new policy will likely be overhang on the stock and even though shares "reflect a bearish scenario," Stephens doesn’t expect a clear-cut resolution "anytime soon," the firm added.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on CDNA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles